Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the sale, the chief operating officer owned 12,737 shares in the company, valued at $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded up $2.24 during mid-day trading on Friday, hitting $67.35. The stock had a trading volume of 3,246,098 shares, compared to its average volume of 2,070,158. Halozyme Therapeutics, Inc. has a one year low of $46.26 and a one year high of $79.50. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $7.92 billion, a P/E ratio of 14.18, a P/E/G ratio of 0.36 and a beta of 0.95. The firm’s 50 day moving average is $67.07 and its 200 day moving average is $64.82.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the business earned $1.27 earnings per share. The business’s revenue was up 22.1% on a year-over-year basis. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of HALO. Redhawk Wealth Advisors Inc. increased its holdings in Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after purchasing an additional 4,827 shares during the period. Intech Investment Management LLC grew its position in shares of Halozyme Therapeutics by 9.9% during the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after buying an additional 13,789 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Halozyme Therapeutics by 19.1% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 444,947 shares of the biopharmaceutical company’s stock valued at $23,146,000 after buying an additional 71,455 shares during the period. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $45,027,000. Finally, HRT Financial LP lifted its stake in Halozyme Therapeutics by 576.1% in the second quarter. HRT Financial LP now owns 467,070 shares of the biopharmaceutical company’s stock worth $24,296,000 after acquiring an additional 397,985 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HALO. The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research report on Tuesday, October 14th. Finally, Citizens Jmp raised their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $75.10.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.